Biomea Fusion (NASDAQ:BMEA) outlined its focus on diabetes and obesity at the Citizens Life Sciences Conference, highlighting two internally developed programs and a series of clinical milestones expected over the coming quarters. President Ramses Erdtmann said the company is funded through the first quarter of 2027 and expects to reach planned milestones without additional financing.
Company focus and two-asset strategy
Erdtmann framed Biomea Fusion as a “diabetes and obesity, period” company with two assets: one he described as a novel approach aimed at addressing underlying disease biology in diabetes, and another aimed at improving the profile of GLP-1–based therapies in obesity. He said both programs were developed in-house and that the company’s approach to targeting key pathways differs from other efforts in the market.
Icovamenib: targeting beta-cell function via menin inhibition
Biomea Fusion’s thesis is that current approaches generally target hyperglycemia (the symptom), rather than the “root cause,” which he described as loss of pancreatic beta-cell capacity. Erdtmann said that by the time a person is diagnosed, roughly 50% of beta cells may already be lost. The company is pursuing menin inhibition based on preclinical and human literature suggesting that reducing menin can improve beta-cell mass and function, including mechanisms observed during pregnancy, when insulin needs rise.
He presented preclinical work in cultured human cadaver islets and animal studies showing that greater menin inhibition corresponded with stronger beta-cell responses under glucose stimulation. He said the company is not aiming to eliminate menin activity entirely, but to reduce it to roughly 50% to 60%.
Early clinical signals, synergy with GLP-1s, and safety discussion
Erdtmann highlighted clinical data previously presented in December, describing a 12-week dosing period in patients characterized as “severe insulin deficient.” He pointed to a reduction in HbA1c of 1.2% and emphasized that the HbA1c curve continued to improve after dosing stopped, which he said supported the company’s premise that a limited course of therapy could restore beta-cell function rather than require chronic dosing.
He also pointed to increases in C-peptide, describing it as a surrogate for insulin production, and said the signal persisted off drug. In a subset of patients who were obese and on GLP-1 therapy, Erdtmann said the company observed HbA1c reductions consistent with a synergistic effect between icovamenib’s mechanism and GLP-1s, noting the company’s islet data showing upregulation of GLP-1 receptors and improved insulin response when combined with semaglutide.
On safety, Erdtmann addressed an earlier FDA hold related to liver findings during dose escalation. He said current studies are using 100 mg dosing and that when dosing remains at 100 mg (rather than escalating to 200 mg), the company has not seen the liver enzyme increases that prompted the hold. He described AST and ALT elevations as largely Grade I, with one Grade II event, and characterized the overall profile as similar to placebo aside from those mild-to-moderate lab changes. As additional context, he noted the company has dosed up to 500 mg in an oncology study of the menin pathway and said it was well tolerated, reinforcing comfort with the 100 mg diabetes dose.
Erdtmann said icovamenib is intended to be a non-chronic agent, contrasting it with other diabetes agents he described as chronic therapies. He also said the company has used a food-effect study to optimize exposure, indicating dosing within a half-hour of a meal improved and standardized drug exposure. In Q&A, he added that higher exposure correlated with better response in earlier work.
Clinical timelines, economics, and an oral obesity program
Biomea Fusion is running two phase II studies in type 2 diabetes that Erdtmann said are funded through their primary endpoints, with readouts expected in the fourth quarter. He said the company’s type 1 diabetes effort had been slowed by the prior hold and that data from patients who completed dosing would be presented in the second quarter once the study is fully vetted. He also described the company’s ambition to reach phase III after discussions with the FDA following phase II, with an internal goal of becoming a phase III company next year.
Erdtmann also discussed where icovamenib may fit in the treatment pathway, arguing that delaying or preventing progression to insulin could offer a meaningful healthcare economic impact. He cited an estimate of roughly $20,000 per patient per year in costs once patients move into insulin-dependent care and said the company hopes icovamenib could provide another option before that transition, though he acknowledged the durability of effect is still being studied.
In obesity, Erdtmann said the company is developing an oral GLP-1–related compound designed to improve patient experience and persistence, citing a U.K. study he said found seven out of ten patients discontinue GLP-1 therapy even when the drug is free. He said the goal is a more patient-friendly pharmacokinetic profile, including improved bioavailability and potentially longer half-life with less “peak to trough” effect.
He presented early animal results comparing weight reduction to data published by Carmot in monkeys, stating Biomea Fusion’s compound showed slightly better mean weight reduction with reduced variability across animals. The obesity program is in a phase I study with single-ascending-dose and multiple-ascending-dose components, and Erdtmann said the company expects data by the end of the second quarter, calling it a near-term value driver.
During Q&A, Erdtmann said the company does not yet know whether patients will require redosing over time and plans follow-on studies to track HbA1c and assess durability. He reiterated the intent to remain non-chronic (“one and done”) where possible, while noting that redosing could be explored in later studies after advancing the core program.
About Biomea Fusion (NASDAQ:BMEA)
Biomea Fusion, Inc (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.
The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.
